Intracranial extraskeletal myxoid chondrosarcoma

Summary

Intracranial extraskeletal myxoid chondrosarcoma (MONDO:0004392) is a disease. A subtype of central nervous system sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intracranial extraskeletal myxoid chondrosarcoma
Mondo ID	MONDO:0004392
DOID	DOID:7903
NCIT	C5462
UMLS	C1334238
MedGen	232660
GARD	0023973
Is cancer (heuristic)	no

Also known as: intracranial extraskeletal myxoid chondrosarcoma

Disease family

This is a subtype of central nervous system sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › central nervous system sarcoma › intracranial extraskeletal myxoid chondrosarcoma

Related subtypes (11): spinal cord sarcoma, brain sarcoma, central nervous system rhabdomyosarcoma, central nervous system angiosarcoma, central nervous system leiomyosarcoma, central nervous system fibrosarcoma, meningeal sarcoma, central nervous system extraskeletal osteosarcoma, malignant peripheral nerve sheath tumor, atypical teratoid rhabdoid tumor, isolated melanotic schwannoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.